Glaxo and Galapagos Ink Anti-Infective Development Deal
 
GlaxoSmithKline and Galapagos this week said that they have entered into a multi-year, strategic alliance to develop novel anti-infective drug candidates.
 
GSK will participate in the alliance through its Infectious Diseases Center of Excellence for Drug Discovery. Under the terms of the agreement, Galapagos will grant GSK options to license product candidates that are directed against up to six anti-infective discovery targets. 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.